» Articles » PMID: 16705063

Deficiency of Carbohydrate-activated Transcription Factor ChREBP Prevents Obesity and Improves Plasma Glucose Control in Leptin-deficient (ob/ob) Mice

Overview
Date 2006 May 18
PMID 16705063
Citations 96
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor carbohydrate response element-binding protein (ChREBP) mediates insulin-independent, glucose-stimulated gene expression of multiple liver enzymes responsible for converting excess carbohydrate to fatty acids for long-term storage. To investigate ChREBP's role in the development of obesity and obesity-associated metabolic dysregulation, ChREBP-deficient mice were intercrossed with ob/ob mice. As a result of deficient leptin expression, ob/ob mice overeat, become obese and resistant to insulin, and display marked elevations in hepatic lipogenesis, gluconeogenesis, and plasma glucose and triglycerides. mRNA expression of all hepatic lipogenic enzymes was significantly lower in ob/ob-ChREBP-/- than in ob/ob mice, resulting in decreased hepatic fatty acid synthesis and normalization of plasma free fatty acid and triglyceride levels. Overall weight gain in addition to adiposity was reduced in the doubly deficient mice. The former was largely attributable to decreased food intake and may result from decreased hypothalamic expression of the appetite-stimulating neuropeptide agouti-related protein. mRNA expression and activity of gluconeogenic enzymes also was lower in the doubly deficient mice, contributing to significantly lower blood glucose levels. The results of this study suggest that inactivation of ChREBP expression not only reduces fat synthesis and obesity in ob/ob mice but also results in improved glucose tolerance and appetite control.

Citing Articles

Integration of metabolomic and transcriptomic analyses reveals novel regulatory functions of the ChREBP transcription factor in energy metabolism.

An J, Astapova I, Zhang G, Cangelosi A, Ilkayeva O, Marchuk H bioRxiv. 2024; .

PMID: 39345566 PMC: 11429843. DOI: 10.1101/2024.09.17.613577.


Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.

Li T, Chiang J Pharmacol Rev. 2024; 76(6):1221-1253.

PMID: 38977324 PMC: 11549937. DOI: 10.1124/pharmrev.124.000978.


Natural compounds proposed for the management of non-alcoholic fatty liver disease.

Merenda T, Juszczak F, Ferier E, Duez P, Patris S, Decleves A Nat Prod Bioprospect. 2024; 14(1):24.

PMID: 38556609 PMC: 10982245. DOI: 10.1007/s13659-024-00445-z.


Hexokinase-linked glycolytic overload and unscheduled glycolysis in hyperglycemia-induced pathogenesis of insulin resistance, beta-cell glucotoxicity, and diabetic vascular complications.

Rabbani N, Thornalley P Front Endocrinol (Lausanne). 2024; 14:1268308.

PMID: 38292764 PMC: 10824962. DOI: 10.3389/fendo.2023.1268308.


ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits.

Singh C, Jin B, Shrestha N, Markhard A, Panda A, Calvo S Cell Metab. 2023; 36(1):144-158.e7.

PMID: 38101397 PMC: 10842884. DOI: 10.1016/j.cmet.2023.11.010.